Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market

Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market

Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabet

NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company devel

Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating

The appointment follows  New c elX's recently announced successful FDA Type B Pre-IND meeting for NC

The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-

FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegopr

The publication further validates NewcelX's ability to develop novel cell therapies through its

Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX'

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human c

NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into

NewcelX (NASDAQ:NCEL) reported quarterly losses of $(2.16) per share. This is a 11.11 percent increa

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches t

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and pl

Outlook for 2026The Company expects 2026 to be a year of accelerated execution, including: Advancin

NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine comp

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes progr

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes progr

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerlan

NLS Pharmaceutics Ltd. (NASDAQ: NCEL - Get Free Report) was the target of a significant growth in sh

Publication strengthens scientific positioning as Company progresses strategic discussions related t

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Ad

ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a cl

4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) and NLS Pharmaceutics (NASDAQ: NCEL - Get

ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"),

USANA Health Sciences (NYSE: USNA - Get Free Report) and NLS Pharmaceutics (NASDAQ: NCEL - Get Free

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company

NLS Pharmaceutics (NASDAQ: NCEL - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free

ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX"